274 related articles for article (PubMed ID: 29627262)
1. Structure-based design and discovery of potent and selective KDM5 inhibitors.
Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
[TBL] [Abstract][Full Text] [Related]
2. The KDM5 family of histone demethylases as targets in oncology drug discovery.
Rasmussen PB; Staller P
Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
[TBL] [Abstract][Full Text] [Related]
3. Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target.
Zheng YC; Chang J; Wang LC; Ren HM; Pang JR; Liu HM
Eur J Med Chem; 2019 Jan; 161():131-140. PubMed ID: 30343192
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
Horton JR; Engstrom A; Zoeller EL; Liu X; Shanks JR; Zhang X; Johns MA; Vertino PM; Fu H; Cheng X
J Biol Chem; 2016 Feb; 291(6):2631-46. PubMed ID: 26645689
[TBL] [Abstract][Full Text] [Related]
5. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.
Vinogradova M; Gehling VS; Gustafson A; Arora S; Tindell CA; Wilson C; Williamson KE; Guler GD; Gangurde P; Manieri W; Busby J; Flynn EM; Lan F; Kim HJ; Odate S; Cochran AG; Liu Y; Wongchenko M; Yang Y; Cheung TK; Maile TM; Lau T; Costa M; Hegde GV; Jackson E; Pitti R; Arnott D; Bailey C; Bellon S; Cummings RT; Albrecht BK; Harmange JC; Kiefer JR; Trojer P; Classon M
Nat Chem Biol; 2016 Jul; 12(7):531-8. PubMed ID: 27214401
[TBL] [Abstract][Full Text] [Related]
6. Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.
Labadie SS; Dragovich PS; Cummings RT; Deshmukh G; Gustafson A; Han N; Harmange JC; Kiefer JR; Li Y; Liang J; Liederer BM; Liu Y; Manieri W; Mao W; Murray L; Ortwine DF; Trojer P; VanderPorten E; Vinogradova M; Wen L
Bioorg Med Chem Lett; 2016 Sep; 26(18):4492-4496. PubMed ID: 27499454
[TBL] [Abstract][Full Text] [Related]
7. JARID1/KDM5 demethylases as cancer targets?
Taylor-Papadimitriou J; Burchell J
Expert Opin Ther Targets; 2017 Jan; 21(1):5-7. PubMed ID: 27882807
[No Abstract] [Full Text] [Related]
8. Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.
Miyake Y; Itoh Y; Hatanaka A; Suzuma Y; Suzuki M; Kodama H; Arai Y; Suzuki T
Bioorg Med Chem; 2019 Mar; 27(6):1119-1129. PubMed ID: 30745098
[TBL] [Abstract][Full Text] [Related]
9. Structural analysis of human KDM5B guides histone demethylase inhibitor development.
Johansson C; Velupillai S; Tumber A; Szykowska A; Hookway ES; Nowak RP; Strain-Damerell C; Gileadi C; Philpott M; Burgess-Brown N; Wu N; Kopec J; Nuzzi A; Steuber H; Egner U; Badock V; Munro S; LaThangue NB; Westaway S; Brown J; Athanasou N; Prinjha R; Brennan PE; Oppermann U
Nat Chem Biol; 2016 Jul; 12(7):539-45. PubMed ID: 27214403
[TBL] [Abstract][Full Text] [Related]
10. Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B).
Zhao B; Liang Q; Ren H; Zhang X; Wu Y; Zhang K; Ma LY; Zheng YC; Liu HM
Eur J Med Chem; 2020 Apr; 192():112161. PubMed ID: 32155529
[TBL] [Abstract][Full Text] [Related]
11. Targeting histone demethylase KDM5B for cancer treatment.
Fu YD; Huang MJ; Guo JW; You YZ; Liu HM; Huang LH; Yu B
Eur J Med Chem; 2020 Dec; 208():112760. PubMed ID: 32883639
[TBL] [Abstract][Full Text] [Related]
12. Identification of potent, selective KDM5 inhibitors.
Gehling VS; Bellon SF; Harmange JC; LeBlanc Y; Poy F; Odate S; Buker S; Lan F; Arora S; Williamson KE; Sandy P; Cummings RT; Bailey CM; Bergeron L; Mao W; Gustafson A; Liu Y; VanderPorten E; Audia JE; Trojer P; Albrecht BK
Bioorg Med Chem Lett; 2016 Sep; 26(17):4350-4. PubMed ID: 27476424
[TBL] [Abstract][Full Text] [Related]
13. Small molecule KDM4s inhibitors as anti-cancer agents.
Lin H; Li Q; Li Q; Zhu J; Gu K; Jiang X; Hu Q; Feng F; Qu W; Chen Y; Sun H
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):777-793. PubMed ID: 29651880
[TBL] [Abstract][Full Text] [Related]
14. 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.
Bavetsias V; Lanigan RM; Ruda GF; Atrash B; McLaughlin MG; Tumber A; Mok NY; Le Bihan YV; Dempster S; Boxall KJ; Jeganathan F; Hatch SB; Savitsky P; Velupillai S; Krojer T; England KS; Sejberg J; Thai C; Donovan A; Pal A; Scozzafava G; Bennett JM; Kawamura A; Johansson C; Szykowska A; Gileadi C; Burgess-Brown NA; von Delft F; Oppermann U; Walters Z; Shipley J; Raynaud FI; Westaway SM; Prinjha RK; Fedorov O; Burke R; Schofield CJ; Westwood IM; Bountra C; Müller S; van Montfort RL; Brennan PE; Blagg J
J Med Chem; 2016 Feb; 59(4):1388-409. PubMed ID: 26741168
[TBL] [Abstract][Full Text] [Related]
15. A KDM5 Inhibitor Increases Global H3K4 Trimethylation Occupancy and Enhances the Biological Efficacy of 5-Aza-2'-Deoxycytidine.
Leadem BR; Kagiampakis I; Wilson C; Cheung TK; Arnott D; Trojer P; Classon M; Easwaran H; Baylin SB
Cancer Res; 2018 Mar; 78(5):1127-1139. PubMed ID: 29282222
[TBL] [Abstract][Full Text] [Related]
16. Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view.
Shokri G; Doudi S; Fathi-Roudsari M; Kouhkan F; Sanati MH
Leuk Res; 2018 May; 68():105-111. PubMed ID: 29602065
[TBL] [Abstract][Full Text] [Related]
17. Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds.
Horton JR; Liu X; Gale M; Wu L; Shanks JR; Zhang X; Webber PJ; Bell JSK; Kales SC; Mott BT; Rai G; Jansen DJ; Henderson MJ; Urban DJ; Hall MD; Simeonov A; Maloney DJ; Johns MA; Fu H; Jadhav A; Vertino PM; Yan Q; Cheng X
Cell Chem Biol; 2016 Jul; 23(7):769-781. PubMed ID: 27427228
[TBL] [Abstract][Full Text] [Related]
18. C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays.
Le Bihan YV; Lanigan RM; Atrash B; McLaughlin MG; Velupillai S; Malcolm AG; England KS; Ruda GF; Mok NY; Tumber A; Tomlin K; Saville H; Shehu E; McAndrew C; Carmichael L; Bennett JM; Jeganathan F; Eve P; Donovan A; Hayes A; Wood F; Raynaud FI; Fedorov O; Brennan PE; Burke R; van Montfort RLM; Rossanese OW; Blagg J; Bavetsias V
Eur J Med Chem; 2019 Sep; 177():316-337. PubMed ID: 31158747
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells.
Montano MM; Yeh IJ; Chen Y; Hernandez C; Kiselar JG; de la Fuente M; Lawes AM; Nieman MT; Kiser PD; Jacobberger J; Exner AA; Lawes MC
Breast Cancer Res; 2019 Dec; 21(1):138. PubMed ID: 31805991
[TBL] [Abstract][Full Text] [Related]
20. Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B.
Pippa S; Mannironi C; Licursi V; Bombardi L; Colotti G; Cundari E; Mollica A; Coluccia A; Naccarato V; La Regina G; Silvestri R; Negri R
Molecules; 2019 May; 24(9):. PubMed ID: 31060229
[No Abstract] [Full Text] [Related]
[Next] [New Search]
